Astra Zeneca
AstraZeneca PLC, a leading global biopharmaceutical company, is headquartered in Cambridge, GB. Founded in 1999 through the merger of Astra AB and Zeneca Group PLC, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in the research, development, and manufacturing of innovative medicines, AstraZeneca focuses on areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to advancing healthcare, AstraZeneca is renowned for its unique portfolio of products, including groundbreaking therapies like Tagrisso and Imfinzi. The company has achieved significant milestones, including rapid vaccine development during the COVID-19 pandemic, solidifying its position as a market leader in the pharmaceutical industry. AstraZeneca continues to drive innovation, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Astra Zeneca's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Zeneca's score of 94 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astra Zeneca's reported carbon emissions
In 2024, AstraZeneca reported total greenhouse gas emissions of approximately 6,000,000,000 kg CO2e, with emissions distributed across various scopes: 125,386,000 kg CO2e (Scope 1), 14,210,000 kg CO2e (Scope 2, market-based), and 5,897,822,000 kg CO2e (Scope 3). The previous year, 2023, saw similar figures with total emissions of about 5,917,160,000 kg CO2e, comprising 180,898,000 kg CO2e (Scope 1), 19,940,000 kg CO2e (Scope 2, market-based), and 5,917,160,000 kg CO2e (Scope 3). AstraZeneca has set ambitious climate commitments, aiming for a 98% absolute reduction in Scope 1 and 2 emissions by 2026, using 2015 as the baseline year. Additionally, the company targets a 50% reduction in Scope 3 emissions by 2030, with specific goals to cut emissions from fuel and energy-related activities, upstream leased assets, and downstream leased assets by 80%, and from the use of sold products by 95%, all from a 2019 baseline. The company is also committed to achieving net-zero greenhouse gas emissions across its value chain by 2045. This commitment includes ensuring that 95% of its suppliers by spend covering purchased goods and services and capital goods have science-based targets by 2025. AstraZeneca's climate initiatives are aligned with the Science Based Targets initiative (SBTi) and reflect a strong commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Zeneca is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
